Leqvio (Inclisiran): How to Safely Stop

Leqvio (inclisiran) represents a small interfering RNA (siRNA) approach to PCSK9 inhibition, administered through subcutaneous injection. The FDA has approved inclisiran for use alongside diet and optimized statin regimens in adults with ASCVD or heterozygous familial hypercholesterolemia (HeFH) requiring further LDL cholesterol reduction. Inclisiran differs mechanistically and in dosing frequency from the monoclonal antibody PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent).

Direct answer: Stopping inclisiran does not cause a withdrawal syndrome and does not require a taper, but it does create a slow-motion decision window. LDL-C does not fall off a cliff after the last dose; it drifts back toward pre-treatment baseline over roughly several months as hepatic PCSK9 mRNA production recovers, and published extension data have not shown LDL-C rising above baseline. For patients with established ASCVD or HeFH, the clinical task is to have a bridging lipid-lowering plan in place before that drift becomes clinically meaningful, not to react after a lipid panel shows the number has already climbed.

The thesis of this page: the risk in stopping inclisiran is almost never the discontinuation itself. It is the gap between the last injection and the next effective therapy being started. A patient who stops inclisiran and simply waits for the next scheduled clinic visit can end up with months of under-treated LDL-C without any acute symptom to flag the problem.

What happens to LDL cholesterol when you stop inclisiran?

Inclisiran silences PCSK9 messenger RNA inside liver cells rather than blocking circulating PCSK9 protein. Because the drug acts upstream, at the mRNA level, its effect does not disappear when the drug clears from plasma. Plasma half-life is short, on the order of hours, but the liver continues producing fewer LDL receptors' worth of degradation signal until it regenerates enough new PCSK9 mRNA and protein to return toward baseline. That recovery is what takes months, not the drug's presence in blood.

Randomized trial extensions of inclisiran (the ORION program) have followed patients after their final dose and reported LDL-C returning toward, but not exceeding, pre-treatment baseline. The exact percentage recovered at any given month varies by publication and by which extension cohort is being described. Readers and clinicians who need a precise number for a specific patient's rebound curve should check the primary ORION extension publications rather than relying on a single rounded figure repeated across secondary sources.

What is established, what is plausible, and what is not established

• Established: Inclisiran's LDL-lowering effect is not sustained indefinitely after the final dose; it wanes over a period of months. No taper is pharmacologically required because the drug does not occupy a receptor that rebounds on withdrawal.
• Plausible but not fully quantified on this page: The exact month-by-month rebound curve, and how it differs by baseline LDL-C, statin background, or hepatic function. Several extension analyses exist; a specific percentage recovered at a specific month should be confirmed against the primary publication before it is used to make an individual treatment decision.
• Not established from the material available here: A guaranteed "no overshoot above baseline" claim for every patient population, and a validated single "bridge activation date" that applies uniformly. Trial-level reassurance is not the same as an individual guarantee.

When stopping inclisiran is medically appropriate

Pregnancy or planned conception

FDA prescribing information for PCSK9-targeted siRNA and monoclonal therapies generally includes reproductive safety warnings based on animal data, and prescribers should treat pregnancy planning as a clear reason to discontinue and discuss alternatives with an obstetric and cardiology team. The current FDA label for Leqvio should be consulted directly for the exact wording and timing recommendation, since label language can be updated. (fda.gov drug label pages: https://www.accessdata.fda.gov/scripts/cder/daf/)

Serious hepatic impairment

Patients with significant hepatic impairment were limited or excluded in the pivotal trials, so dosing in this population is not well established. Discontinuation pending hepatology and cardiology input is a reasonable, individualized decision rather than a labeled rule to apply automatically.

Intolerable injection-site reactions

Injection-site reactions have been reported in inclisiran trials, generally described as more common than placebo but mostly mild and transient. We do not have a verified, source-confirmed rate to cite precisely on this page; a clinician managing a patient with a severe or persistent reaction should refer to the primary trial safety tables rather than a rounded percentage repeated secondhand.

Insurance loss or access failure

Coverage disruption is commonly cited anecdotally as a reason patients stop specialty lipid-lowering therapy, including inclisiran. We do not have a verified, page-specific statistic on denial rates to report here. The practical point does not depend on the exact percentage: if a patient reports a coverage gap, the bridging conversation should start immediately, not after the next scheduled dose is missed.

The offset window: why timing matters more than the exact number

For a patient with established ASCVD whose LDL-C was substantially elevated before treatment and well controlled on inclisiran, allowing LDL-C to drift back toward baseline for many months without any intervening therapy runs counter to guideline-directed LDL-C targets for very-high-risk patients. The ACC/AHA cholesterol guideline framework generally supports LDL-C targets below 70 mg/dL for very-high-risk ASCVD patients; the current guideline document should be checked for the specific version in effect, since guidelines are periodically updated.

The clinically useful reframe is this: the offset from inclisiner is not a cliff, it is a slope. A slope gives time to act, but only if someone is watching it and has already decided what the next step will be.

Bridging strategies after inclisiran discontinuation

Clinician discussion and monitoring framework

This framework is a starting point for a conversation between prescriber and patient. It is not a substitute for individualized assessment, and none of the checkpoints below override current FDA labeling or an accountable clinical guideline where one exists.

Checkpoint 1: Before the last planned dose (or as soon as discontinuation is decided)

• Confirm the reason for stopping (pregnancy, hepatic concern, injection-site reaction, access failure, or shared decision to pause).
• Obtain a fasting lipid panel to record the LDL-C value at or near the drug's peak effect.
• Decide, in advance, which bridging option applies if LDL-C is expected to be needed (see comparison table below). Do not leave this decision for the point at which LDL-C has already risen.

Checkpoint 2: Roughly 3 months after the last dose

• Recheck fasting LDL-C. This is early enough that if the bridge is inadequate, there is still time to escalate before a prolonged period of under-treatment accumulates.
• If LDL-C is already trending toward or above the patient's individualized target, escalate the bridging regimen now rather than waiting for a scheduled annual visit.

Checkpoint 3: Roughly 6 months after the last dose

• Recheck fasting LDL-C again. By this point most published extension data describe LDL-C as substantially returned toward baseline in patients without a bridge.
• If the reason for stopping was temporary (a resolvable coverage gap, a resolved hepatic concern), this is a reasonable point to reassess whether inclisiran can be restarted per the standard loading schedule.

Checkpoint 4: 12 months

• Confirm sustained control on whatever regimen is now in place.
• Revisit whether inclisiran, or an alternative PCSK9-directed therapy, is now more accessible.

Stop and escalate outside this framework if:

• LDL-C rises substantially above the patient's individualized target at any monitoring point, particularly in a patient with ASCVD or HeFH. This warrants earlier specialist input rather than waiting for the next scheduled checkpoint.
• New symptoms suggestive of a cardiovascular event occur at any point. This is urgent care territory, not a lipid-panel timing question, regardless of where the patient is in the discontinuation window.
• Hepatic symptoms (jaundice, right upper quadrant pain, dark urine) emerge if hepatic impairment was the reason for stopping. This should prompt hepatology evaluation, not routine lipid monitoring alone.

Where label guidance ends and individualized judgment begins: The FDA label defines the approved dosing schedule, the approved population, and known contraindications. It does not define a universal discontinuation protocol, a universal rebound curve, or a universal bridging algorithm. The checkpoints above and the comparison table below reflect a reasonable clinical approach built from the general mechanism and named trials in the lipid-lowering literature, not a labeled requirement. A patient's actual bridging choice depends on baseline LDL-C, statin tolerance, renal and hepatic status, pregnancy plans, and access, and should be made with the prescribing clinician.

Comparison of bridging options

Exact percentage reductions for each option vary by trial population and background therapy. Readers should treat any single rounded percentage (for example, "adds 18% LDL-C reduction") as an approximation pending confirmation in the primary trial report for the specific agent and population in question.

How inclisiran works, and why no taper is needed

Inclisiran is delivered to hepatocytes via conjugation to a GalNAc (N-acetylgalactosamine) ligand, which targets liver uptake. Once inside the cell, it loads into the RNA-induced silencing complex and degrades PCSK9 messenger RNA, reducing production of PCSK9 protein. Because PCSK9 protein normally promotes degradation of LDL receptors, less PCSK9 means more LDL receptors remain on the hepatocyte surface to clear LDL-C from the blood.

This is mechanistically different from monoclonal antibodies like evolocumab and alirocumab, which bind and neutralize PCSK9 protein already circulating in blood. Antibody effects last as long as meaningful antibody levels persist, generally weeks. Inclisiran's effect lasts as long as the silencing complex remains active in liver cells and until new PCSK9 mRNA and protein synthesis recovers, which is why it can be dosed twice yearly.

Because inclisiran does not occupy a receptor that upregulates during chronic blockade, no withdrawal-type rebound above baseline is described in the published extension literature, and no taper is pharmacologically indicated. The practical discontinuation step is simple: the last dose is the last dose. The complexity is entirely in planning what comes next, not in how the drug itself is stopped.

What inclisiran does not do

Inclisiran's approved effect is on LDL-C. It is not established as a meaningful therapy for triglycerides, HDL-C, or inflammatory markers such as hsCRP. Patients whose primary lipid concern is high triglycerides or low HDL-C should not expect stopping inclisiran to change those numbers, because inclisiran was not treating them in the first place.

Special populations

Familial hypercholesterolemia (HeFH): Patients with HeFH generally need deeper and more consistent LDL-C lowering than patients with ASCVD alone. If inclisiran is stopped in this population, a monoclonal PCSK9 inhibitor is a reasonable preferred bridge given the depth of reduction usually required, though the specific target should follow current lipid society guidance for the individual patient rather than a single number applied universally.

Older adults: Twice-yearly dosing can be an adherence advantage in patients managing multiple daily medications. If inclisiran is stopped to simplify a regimen, consider that a daily bridging pill may itself introduce an adherence problem the original regimen did not have. A monthly injectable monoclonal PCSK9 inhibitor may fit better than a daily oral bridge in some patients, but this is a judgment call, not a rule.

Renal impairment: Renal function has not been reported as a barrier to inclisiran use across a range of kidney function in trial populations, according to general prescribing information. If the reason for stopping is unrelated to the kidneys, bridging agent choice should still account for renal status, since statin dosing and monoclonal PCSK9 inhibitor use both carry their own renal-related considerations that should be reviewed with a nephrology or cardiology team when relevant.

Conversations to have before the final injection

The most useful discontinuation planning happens before the decision to stop is final. At any visit where access, tolerance, or life plans (pregnancy, upcoming surgery, insurance changes) are uncertain, the prescribing clinician and patient should discuss explicitly what the plan is if the next dose is delayed or does not happen. Framing inclisiran as ongoing management of a chronic condition, rather than a finite course of treatment, makes an eventual pause or stop less confusing when it occurs.

Frequently asked questions

References

1. U.S. Food and Drug Administration. Drug approvals and databases, including current Leqvio (inclisiran) prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/

Additional evidence referenced in this article by name, including the ORION program trials (inclisiran), FOURIER (evolocumab), IMPROVE-IT (ezetimibe), and CLEAR Outcomes (bempedoic acid), are widely published in the cardiovascular literature. Specific numeric claims attributed to these trials in earlier drafts of this page could not be verified against a confirmed primary-source link for this review and have been generalized or removed pending direct confirmation against the original publications. Editors should attach verified PubMed or journal links to these trials before publication if precise effect sizes are needed.